Expanded Use of CBD in Medical Research Gets FDA Approval – KTALnews.com
FDA approval of expanded CBD research protocols marks a significant advancement in medical research. This development enhances the quality and scope of clinical evidence available for CBD. Expanded CBD research protocols will help guide better patient…
CBD Shows Promise But Lacks Broad Regulatory Approval: A Sobering Review of the Evidence
The CBD pharmacology regulatory context reveals a narrow evidence base supporting broad approval. Most CBD products lack pharmaceutical-grade quality and regulatory endorsement. This 2024 review highlights the need for rigorous clinical trials and…
Comprehensive Guide to Endocannabinoid System Clinical Research
This endocannabinoid system clinical research guide highlights genetic variants linked to psychiatric disorders. The study identifies key SNPs in the DAGLA gene associated with mental health risks. Understanding these findings aids in contextualizing the…
MIRA Pharmaceuticals Reports MIRA-55 Avoids CNS Side Effects
Synthetic cannabinoids CNS side effects have limited clinical use of many compounds. MIRA Pharmaceuticals reports MIRA-55 shows no THC- or rimonabant-associated CNS side effects in preclinical studies. This research could advance cannabinoid drug…
Mira-55 Shows No THC- or Rimonabant-Linked CNS Side Effects in Preclinical Tests
Mira-55 represents a breakthrough in cb1 receptor modulation by avoiding CNS side effects linked to THC and rimonabant. This novel compound targets CB1 receptors for metabolic health benefits without psychoactive risks. Preclinical tests show promising…
Yale and McGill Collaborate to Expand Cannabis Research
Academic partnerships cannabis research is growing with Yale and McGill's new collaboration. This effort aims to enhance clinical cannabis studies and infrastructure. The partnership promises to accelerate evidence-based protocols for clinicians.
The Endocannabinoid System and Enhanced Analgesia of a Novel NSAID Derivative
This article explores the hydrogen sulfide releasing NSAID derivative ATB-352 and its enhanced analgesic effects mediated by the endocannabinoid system. ATB-352 shows improved gastrointestinal safety compared to traditional NSAIDs. The role of endogenous…